




Signs, Symptoms & Mechanism of Toxicity

Acetaminophen toxicity can occur after one ingested overdose (acute ingestion) or as a result of repeated, supratherapeutic doses (chronic ingestion)

Typical presentation:

Clinical manifestations of acetaminophen overdose can be **gradual and nonspecific**.

Four clinical stages of acetaminophen toxicity, based on time after ingestion:

- **Stage 1: 12 to 24 hours** - anorexia, malaise, diaphoresis, nausea, and vomiting.
- **Stage 2: 36 to 48 hours** - variable clinical presentation, may include elevation of liver enzyme levels, liver enlargement, or right upper quadrant abdominal pain. Patients also may be asymptomatic.
- **Stage 3: 3 to 5 days** - recurrence of anorexia, nausea, vomiting, and malaise. Liver enzyme levels may worsen and be accompanied by signs of liver failure, including jaundice, hypoglycemia, coagulopathy, and encephalopathy.
- **Stage 4:** - Complete recovery **or** progression to liver failure.

Mechanism of toxicity:

- Acetaminophen is metabolized mainly in the liver by conjugation with sulfate and glucuronide.
- When an excessive amount of acetaminophen is present, it overwhelms the normal conjugation pathway, and metabolism is channeled to the cytochrome P-450 pathway, which produces the **toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI)**.
- **NAPQI is detoxified by glutathione; however, when glutathione becomes depleted, NAPQI binds directly to hepatocytes, causing cellular necrosis.**

Argentieri J, Morrone K, Pollack Y. Acetaminophen and Ibuprofen overdosage.
Pediatr Rev. 2012 Apr;33(4):188-9. doi: 10.1542/pir.33-4-188. PMID: 22474118.


[Return to Acute APAP Algorithm](#)

Severity Assessment

Revised Rumack-Matthew Nomogram for the Acute Ingestion of Acetaminophen

Acetylcysteine should be initiated if a serum or plasma acetaminophen blood concentration drawn 4 to 24 hours after ingestion falls on or above the treatment line (blue area in nomogram).

If the concentration falls on or above the **high-risk line**, discuss with Toxicology and/or COPC if High Dose acetylcysteine should be given.



Reference: Dart RC, Mullins ME, Matoushek T, et al. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. *JAMA Netw Open.* 2023;6(8):e2327739. doi:10.1001/jamanetworkopen.2023.27739

[Return Acute APAP Algorithm](#)

Concern for Moderate-Severe Hepatotoxicity


III appearing or encephalopathic in with concern for Acetaminophen (APAP) ingestion

Call Poison Control

- **Cardiac Monitors**
- **Place IV**
- **Obtain**
 - iSTAT
 - Complete metabolic panel
 - Lactate
 - Ammonia
 - PT/INR

Admit to PICU with early consultation with Hepatology team

[Return to Acute APAP Algorithm](#)



Oral NAC Therapy

Loading

- 140 mg/kg (max 15 grams) PO

Maintenance

- 70 mg/kg (max 7.5 grams) PO 4 hours after loading dose and every 4 hours x 24 hours
- Obtain repeat labs 24 hours AFTER starting NAC:
 - APAP level and AST
 - Add ALT, total and direct bilirubin & PT/INR if GI symptoms or previously-elevated AST

To optimize tolerance of PO NAC

- Dilute to 5% solution in orange juice or soft drink
- Chilled/over ice
- Sip through straw poked in hole of saran wrap covering cup to reduce odor
- If normal QT on EKG, use ondansetron to prevent emesis
- No need to repeat dose if emesis > 1 hour later & does not smell like NAC

[Return to NAC Therapy Algorithm](#)

[Patient at BHP/PCD](#)

3-Bag NAC Therapy

Loading

- 150 mg/kg (max 15 grams) IV over 1 hour

Second

- 50 mg/kg (max 5 grams) IV over next 4 hours

Third

- 100 mg/kg (max 10 grams) IV over next 16 hours
- **Draw APAP level and AST 2 hours prior to completion of last bag of NAC**
- Add ALT, total and direct bilirubin & PT/INR if GI symptoms **or** previously elevated AST

[**Return to NAC
Therapy Algorithm**](#)

Patient at Behavioral Health Pavilion/ Psychiatric Crisis Department BHP/PCD

In the instances where transport or IV access is delayed, **initiation of oral NAC should be considered at the Behavioral Health Pavilion.** Studies have shown that oral NAC is as effective as IV NAC in reducing hepatotoxicity in acetaminophen toxicity, though some patients may not tolerate the oral product due to nausea/vomiting.

Acetylcysteine 20% oral solution is now stocked in the BH1A Pyxis Station located in the PCD medication room. *This product comes as an oral solution in glass vials and should be diluted prior to administration.*

Prior to ordering NAC, physicians should assess if oral NAC would be appropriate to start in patients with **acetaminophen ingestion**. As always, contact Poison Control Center (800-222-1222) with any questions/concerns.

- When to ***emergently*** transfer patients to MCED (via ambulance) for IV treatment:
 - Altered mental status
 - “Massive” ingestion
 - Definition of “massive” may vary; generally if
 - 4-hr acetaminophen serum concentration > 300 mcg/mL **or**
 - Ingestion of greater than 32 g of acetaminophen
 - Delay in safe car transportation to main campus and patient unable to tolerate oral product
 - Any other medical instability or if recommended by Poison Control Center

[Return to NAC Therapy Algorithm](#)

[Return to Oral NAC Therapy](#)

Admission Criteria

- APAP level at or above treatment line on nomogram
- Intentional overdose not ruled out
- Unable to medically clear beyond presenting symptoms
- Consider admission to Pediatric Intensive Care Unit if there is altered mental status, respiratory failure, or signs of shock

[Return to Acute APAP Algorithm](#)

[Return to NAC Therapy Algorithm](#)

Quality Measures

Process Measure:

- Pathway Visualization
- Order set use
- Time from APAP level to start of NAC treatment

Balancing Measure:

- ED Length of stay

[Return to Acute APAP Algorithm](#)

Key References

- Hendrickson RG, McKeown NJ. Acetaminophen. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS. eds. Goldfrank's Toxicologic Emergencies, 11e. McGraw-Hill Education; 2019. Accessed September 25, 2025. <https://accesspharmacy.mhmedical.com/content.aspx?bookid=2569§ionid=210270383>
- Hendrickson RG, Howland M. N-Acetylcysteine. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS. eds. Goldfrank's Toxicologic Emergencies, 11e. McGraw-Hill Education; 2019. Accessed September 25, 2025. <https://accesspharmacy.mhmedical.com/content.aspx?bookid=2569§ionid=210261914>
- Smollin C. Acetaminophen. In: Olson K, Smollin C, eds. Poisoning & Drug overdose, 8e. McGraw-Hill Education; 2022.
- Dart RC, Mullins ME, Matoushek T, et al. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. *JAMA Netw Open*. 2023;6(8):e2327739. doi:10.1001/jamanetworkopen.2023.27739
- Hodgman MJ, Garrard AR. A review of acetaminophen poisoning. *Crit Care Clin*. 2012;28(4):499-516. doi:10.1016/j.ccc.2012.07.006
- Spiller HA, Winter ML, Klein-Schwartz W, Bangh SA. Efficacy of activated charcoal administered more than four hours after acetaminophen overdose. *J Emerg Med*. 2006;30(1):1-5. doi:10.1016/j.jemermed.2005.02.019
- Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. *Br Med J*. 1979;2(6198):1097-1100. doi:10.1136/bmj.2.6198.1097
- Yarema MC, Johnson DW, Berlin RJ, et al. Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. *Ann Emerg Med*. 2009;54(4):606-614. doi:10.1016/j.annemergmed.2009.05.010
- Dart RC, Mullins ME, Matoushek T, et al. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. *JAMA Netw Open*. 2023;6(8):e2327739. doi:10.1001/jamanetworkopen.2023.27739

[Return to Acute APAP Algorithm](#)

Team & Process

Pathway Development Team:

Leaders:

Emergency Medicine:

Aarti Gaglani, MD

Poison Center:

Marcel Casavant, MD
Hannah Hays, MD

Hepatology:

Carol Potter, MD

Pharmacy:

Kimberly Jones, PharmD, BCPS, BCPPS

Members:

Emergency Medicine:

Aarti Gaglani, MD

Maegan Reynolds MD

Pediatrics Resident:

Megan Fennel, MD

Clinical Pathways Program:

Medical Director – Emergency Medicine:

Aarti Gaglani, MD

Medical Director – Clinical Informatics & Emergency Medicine:

Laura Rust, MD, MPH

Business & Development Manager:

Rekha Voruganti, MBOE, LSSBB

Program Coordinators:

Tahje Brown, MBA

Tara Dinh, BS

Clinical Pathway Approved:

Medical Director – Associate Chief Quality Officer, Center for Clinical Excellence:

Ryan Bode, MD, MBOE

Origination Date: *December, 2021*

Last Revision Date: *June, 2026*

Next Revision Date: *June, 2031*

Clinical Pathway Development

This clinical pathway was developed using the process described in the NCH Clinical Pathway Development Manual Version 6, 2022. Clinical Pathways at Nationwide Children's Hospital (NCH) are standards which provide general guidance to clinicians. Patient choice, clinician judgment, and other relevant factors in diagnosing and treating patients remain central to the selection of diagnostic tests and therapy. The ordering provider assumes all risks associated with care decisions. NCH assumes no responsibility for any adverse consequences, errors, or omissions that may arise from the use or reliance on these guidelines. NCH's clinical pathways are reviewed periodically for consistency with new evidence; however, new developments may not be represented, and NCH makes no guarantees, representations, or warranties with respect to the information provided in this clinical pathway.

Copyright © 2023. Nationwide Children's Hospital. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without the express written permission of Nationwide Children's Hospital.

For more information about our pathways and program please contact:
ClinicalPathways@NationwideChildrens.org

[Return to Acute APAP Algorithm](#)